functionality, we also demonstrate that FPSCs from OA donors respond to the application of physiological levels of cyclic hydrostatic pressure by increasing aggrecan gene expression and the production of sulfated glycosaminoglycans. We next explored whether cartilaginous grafts could be engineered with diseased human FPSCs using a self-assembly or scaffold-free approach. After examining a range of culture conditions, it was found that continuous supplementation with both TGF-β3 and BMP-6 promoted the development of tissues rich in proteoglycans and type II collagen. The final phase of the study sought to scale-up this approach to engineer cartilaginous grafts of clinically relevant dimensions (≥2 cm in diameter) by assembling FPSCs onto electrospun PLLA fibre membranes. Over 6 weeks in culture it was possible to generate robust, flexible cartilage-like grafts of scale, opening up the possibility that tissues engineered using FPSCs derived from OA patients could potentially be used to resurface large areas of joint surfaces damaged by trauma or disease.
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Introduction
A number of chondrocyte-based approaches have been developed for treating small focal defects within the articular surface of synovial joints [1] [2] [3] [4] . In spite of the significant advances that have been made in the field of articular cartilage tissue engineering and regenerative medicine, no cell based therapy has been developed to treat more advanced joint diseases like osteoarthritis (OA). This is a far greater clinical problem than the treatment of focal cartilage defects, with the significant damage to the articular surface that characterises this disease ultimately necessitating replacement of the native joint with a metal and polymer prosthesis.
In recent years there has been increased interest in the use of stem cells as part of a new treatment paradigm for OA 5 . One putative route to joint regeneration would be to replace the entire articular surface of a diseased joint with a tissue engineered cartilaginous or osteochondral graft. Realising such a transformative treatment option for OA requires a number of biological and technical challenges to be overcome, in particular the identification of a cell source suitable for use in the OA patient population, as well as the development of novel approaches for engineering functional grafts of a geometric scale necessary to resurface an entire joint.
It has recently been demonstrated that large scale cartilaginous grafts can be engineered by seeding human chondrocytes into Hyaff-11 non-woven meshes and maintaining the construct in a flow perfusion bioreactor 6 . While such an approach provides a promising putative treatment option for repairing large cartilaginous defects, it remains uncertain if chondrocytes isolated from articular cartilage represent a viable cell source for the osteoarthritic patient population due to age and disease related declines in their chondrogenic potential 7, 8 . This had led to increased interest in the use of stem cells for cartilage tissue engineering applications 5 , from embryonic stem cells 9 to adult mesenchymal stem cells or multipotent stromal cells (MSCs) isolated from tissues such as bone marrow 10- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 . It is also hypothesized that diseased FPSCs can be used to engineer cartilaginous grafts of clinically relevant dimensions (>2 cm) for the osteoarthritic patient population using such a scaffold-free or self-assembly approach.
Materials and Methods

Cell isolation and expansion
Ethical approval for the study was obtained from the institutional review board of the Mater Misericordiae University Hospital with infrapatellar fat pad tissue being obtained from patients either with knee osteoarthritis (OA) at joint arthroplasty or from patients undergoing ligament reconstruction without symptoms of osteoarthritis (where small biopsies of IFP tissue were removed). Informed signed consent was pre-obtained from each patient. Fat pad tissue was maintained in sterile phosphate buffer saline (PBS) and transferred immediately to Trinity Centre for Bioengineering for further processing. Fibrous tissue was carefully removed from the fat pad and discarded. The remaining tissue was weighed, washed thoroughly in PBS and diced, followed by incubation under constant rotation at 37°C with high-glucose Dulbecco's Modified Eagle Medium (hgDMEM, GlutaMAXTM) (GIBCO, Biosciences, Ireland) containing 1% penicillin (100 U/ml)-streptomycin (100 µg/ml) and collagenase type II (4 ml solution/g tissue, 750 U/ml, Worthington Biochemical, LanganBach Services, Ireland) for 4 hours. Cells were filtered through serial cell sieves (Falcon, Sarstedt, Ireland) with pore size from 100 µm, 70 µm to 40 µm. The isolated cells were cultured in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Chondrogenesis in pellet culture
To compare the chondrogenic potential of FPSCs obtained from tissue defined macroscopically as either healthy or OA in nature, cells were isolated from 3 healthy donors and 3 OA donors and cultured separately until the end of passage (P) 1 or 2. Cells from either healthy or diseased (OA) donors were then pooled together and used to form pellets.
Additional pellets were also generated using FPSCs from individual (i.e. not pooled) donors.
Pellets were formed by centrifuging 250,000 cells in 1.5 ml conical eppendorf tubes at 650 g for 5 min. Pellets were maintained in chondrogenic medium, consisting of hgDMEM GlutaMax supplemented with penicillin (100 U/ml)-streptomycin (100 µg/ml) (Invitrogen, Paisley, UK), 100 µg/ml sodium pyruvate, 40 µg/ml L-proline, 50 µg/ml L-ascorbic acid-2-phosphate, 4.7 µg/ml linoleic acid, 1.5 mg/ml bovine serum albumin, 1x insulin-transferrinselenium, 100 mM dexamethasone (all from Sigma-Aldrich) and 10 ng/ml of recombinant human transforming growth factor-β3 (TGF-β3; Prospect-Tany TechnoGene Ltd., Israel).
Additional pellets were also supplemented with 10 ng/ml recombinant human bone morphogenic protein-6 (BMP-6; R&D systems). Pellets were cultured at 37 ºC and 5% O 2 for a period of 28 days. 1ml chondrogenic medium was supplied to each pellet and the medium was exchanged twice weekly. 
Self-assembly in Transwell insert
4 million cells were resuspended in 100 µl of expansion medium and seeded onto 6.5 mm polyester (PET) transwell inserts (Corning, VWR, Ireland). Each insert was allowed to sit in a 6-well plate overnight to allow initial cell attachment onto the membrane (Fig. 1 ).
Expansion medium (9 ml) was supplied for the first 2 days of culture to minimize the contraction that is mediated by the addition of chondrogenic media. Following this 2 day period, cell seeded inserts were supplemented with chondrogenic medium for a further 6 weeks at 20% O 2 . Additional self-assembled tissues were also maintained at 5% O 2 . Medium exchanges were performed twice weekly.
Engineering scaled-up self-assembled constructs
To scale up the geometry of the self-assembled construct, larger inserts generated using PLLA electrospun fibre membranes (20mm in diameter and 50um in thickness, The
Electrospinning Company, UK) were wetted with 15% ethanol, washed 3 times in PBS and immersed in expansion medium. Approximately 38 million cells were resuspended in 700 µl of expansion medium and carefully seeded onto the inserts. These constructs were then cultured in expansion medium for the first 2 days, followed by culture in a chondrogenic medium for 6 weeks at 20% O 2 . For the first week of culture these constructs were kept in 6-well plates. Due to volume constraints within these 6-well plates, media was exchanged daily.
After one week of culture, the constructs were released from inserts and maintained in agarose-coated 10 cm petri dishes, where media was changed twice weekly. . Pellets were transferred to sterilized, heat-sealed bags filled with chondrogenic medium for the 2-hour loading period.
Application of cyclic hydrostatic pressure (HP)
The bags for HP loading were placed in a water-filled pressure vessel while FS control groups (also contained in heat-sealed bags) were placed in an open water bath, both maintained at 37 ºC. After 2 hours of loading, pellets were removed from the bags and transferred to an incubator maintained at 5% O 2 .
Biochemical analysis
Pellet and self-assembled constructs were digested in papain (125 ug/mL) in 0. Human ligament and cartilage were included as controls for collagen type I and collagen type II respectively.
Histology and immunochemistry
Real-time PCR
Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) was used to determine the relative changes in gene expression between (1) healthy and diseased FPSCs undergoing TGF-β3 mediated chondrogenesis and (2) unloaded pellets and those subjected to HP. Total RNA was extracted from pellets following 28 days of culture. Pellet construct pooling was performed for all groups, with a total of 3 pellets pooled per group. Total cellular RNA was extracted from each pellet group by physical homogenization using a pestle (Hs02798991-g1) were used in each study. qRT-PCR was performed using an ABI 7500
Sequence Detection system (Applied Biosystems). A 20 µL volume was added to each well Relative quantification values are presented as fold changes in gene expression plus/minus the standard deviation of the mean relative to the control group, which was normalized to one.
Mechanical testing
Constructs were mechanically assessed using a protocol described previously 51 . Briefly,
constructs from each group were tested in unconfined compression between impermeable platens using a standard Zwick testing machine with a 5 N load cell (Zwick Z005, Roell, Germany). A ramp and hold cycle with a ramp displacement of 1 µm/s until 10 % strain was 
Statistics
Numerical and graphical results are presented as mean±standard deviation (3-4 samples per donor/group for each experimental arm). Statistics were performed using R (The R Foundation for Statistical Computing, Vienna, Austria). Groups were analyzed for significant differences using a linear model for analysis of variance with multiple factors and interactions between these factors also examined. Tukey's HSD test for multiple comparisons was used as post-tests. Significance was accepted at a level of p < 0.05.
Results
FPSCs isolated from OA donors display a comparable chondrogenic capacity to cells from healthy donors
As expected, some donor-to-donor variability was observed in the chondrogenic capacity of infrapatellar fat pad derived stem cells (FPSCs), although all donors demonstrated the ability to differentiate along the chondrogenic pathway (see Supplementary Figure 1 ). In general the levels of glycosaminoglycan and collagen accumulation observed for these donors were comparable to previous studies from our lab using diseased human FPSCs 38, 52 . To explore if the chondrogenic capacity of FPSCs is diminished with the development of joint diseases like osteoarthritis, cartilaginous pellets were formed using cells pooled from both healthy (isolated from patients undergoing ligament reconstruction) and osteoarthritic (OA) donors. Table 1 ).
FPSCs from OA donors respond anabolically to the application of hydrostatic pressure
A characteristic of chondrocytes is to respond to the application of cyclic hydrostatic pressure (HP) with increases in cartilage extracellular matrix production 53 . To confirm that chondrogenically primed FPSCs isolated from OA donors possess the capacity to respond anabolically to such a mechanical cue, cell pellets were subjected to HP stimulation for 14 days after an initial 14 day period of free swelling (FS) culture. The application of HP to FPSCs led to a significant increase in sGAG synthesis compared to FPSCs that were maintained in FS conditions for the entire 28 day culture period (Fig. 3A) , but had no effect on DNA levels or collagen synthesis. Comparable results were obtained at the mRNA level.
FPSCs from OA donors responded to the application of HP with a significant increase in the expression of aggrecan. No significant difference was observed in the expression of type I collagen, type II collagen or type X collagen following the application of HP (Fig. 3B ). PET transwell inserts and maintained in chondrogenic media for 6 weeks in either normoxic (20%) or low oxygen conditions (5%). The resulting engineered tissues were robust and easily handleable (Fig. 4A) , with sGAG and collagen contents exceeding 1% of tissue wet weight (Fig. 4B) . Grafts engineered at 5% O 2 had a slightly higher DNA content, comparable sGAG content and lower collagen content to constructs generated in normoxic conditions (Fig. 4B ). The external oxygen tension did not influence the resulting mechanical properties of the engineered tissue (Fig. 4C) . The spatial accumulation of proteoglycans, as evidenced by Alcain Blue staining, was relatively homogenous, while greater type II collagen accumulation occurred in the upper half of the engineered graft (Fig. 4D) .
A self-assembly approach can be used to engineer cartilaginous grafts using diseased human FPSCs
BMP-6 enhances the development self-assembled cartilaginous grafts
We next sought to explore how different media supplementation conditions, specifically those that have previously been shown to be beneficial for cartilage tissue engineering applications, would influence the development of grafts generated using diseased FPSCs using a self-assembly approach. (It should be noted that these experiments were performed independently using FPSCs from different donors). Withdrawal of TGF-β from the media after 2 weeks of culture, which has been shown to enhance the development of cartilaginous tissues engineered using primary juvenile bovine chondrocytes embedded into agarose hydrogels 54 , led to the development of inferior grafts (see Supplementary Figure 2 ).
Similarly, supplementation with 10% FBS, which we have previously demonstrated enhances the development of cartilaginous tissues engineered using diseased human FPSCs , also negatively impacted the development of the engineered graft (Fig. 5) . In contrast, supplementation with BMP-6 was found to enhance the accumulation of both sGAG and collagen (when measured in µg) within the engineered tissue, at least in part by promoting the proliferation of FPSCs as evident by the higher DNA content within these tissues (Fig. 6B) . Tissues engineered in the presence of BMP-6 also stained strongly for type II collagen (Fig. 6C) . Comparable staining for type I and type X collagen was observed in the two groups.
Grafts of clinically relevant dimensions can be engineered by self-assembly of human FPSCs on electrospun PLLA fibres
In a final proof-of-principal study, we sought to determine if the self-assembly approach could be scaled up to engineer cartilaginous grafts of clinically relevant dimensions. To this end, approximately 40 million FPSCs derived from OA donors were seeded onto electrospun PLLA fibre membranes 2 cm in diameter. This led to the development of robust, flexible cartilaginous grafts (Fig. 7A) . Supplementation with BMP-6 again enhanced the development of these engineered tissues (Fig. 7B) . The tissues stained reasonably homogenously for Alcian Blue, although certain regions were stained less intensely for proteoglycans towards the bottom of the graft (Fig. 7C ). Collagen accumulation generally appeared greater towards the surface of the engineered grafts, as evident by Picrosirius Red staining.
Discussion
Perhaps the greatest challenge in orthopaedic tissue engineering and regenerative medicine is the development of novel therapies for the treatment of osteoarthritis. If this is to be realised .
In contrast to our own previous findings using the pellet culture system 38 and in fibrin hydrogels 31 , we found that low oxygen conditions did not enhance chondrogenesis of FPSCs in the transwell system. Murdoch and colleagues also reported that preliminary experiments at a lowered oxygen tension (5%) did not enhance chondrogenic differentiation of BM derived MSCs in transwell cultures 39 . The high cell density and associated levels of oxygen consumption may be leading to the development of anoxic conditions towards the bottom of Regardless of any nutrient transport issues, it should be noted that the composition of these engineered tissues, in terms of sGAG content, are comparable to that generated using culture expanded human chondrocytes cultured on porous scaffolds within perfusion bioreactors 6 .
This provides further support for the use of FPSCs from diseased joints for clinical cartilage tissue engineering applications.
A potential concern with the grafts generated using this approach was that the .
In agreement with our previous studies using human FPSCs embedded into agarose hydrogels, we found that supplementation with BMP-6 lead to increases in the absolute DNA, sGAG and collagen content of the engineered tissues 76 . In subcutaneous fat derived . Such enhanced extracellular matrix deposition is clearly beneficial for cartilage tissue engineering applications, although it should be noted that grafts generated in the presence of BMP-6 appear more geometrically inhomogeneous than those generated in the presence of TGF-β3
only. We believe that this may be due to the side walls of the transwell insert (see Fig. 1a) providing a surface to preferentially guide the migration and/or deposition of extracellular matrix within this region of the insert, which is particularly prevalent in the presence of BMP-6 where significant cell proliferation is observed. Such inhomogeneity is clearly a challenge for cartilage tissue engineering applications.
The final part of this study demonstrated that it is possible to engineer grafts of clinically relevant dimensions (≥ 2cm) using diseased FPSCs seeded onto electrospun PLLA fibre membranes. To overcome the issue discussed above of preferential tissue growth around the periphery of the transwell insert, the engineered grafts were carefully removed from the inserts after one week of culture, which lead to the development of a more geometrically uniform tissue. The composition of cartilaginous tissues generated on these larger PLLA membranes were reasonably similar to that generated on the smaller PET inserts, albeit the larger tissues were perhaps slightly more inhomogeneous in their spatial composition, with certain regions of the grafts staining less intensely for collagen and proteoglycans (Fig. 7) .
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